AR075235A1 - Derivados de indol como agentes anticancer. - Google Patents
Derivados de indol como agentes anticancer.Info
- Publication number
- AR075235A1 AR075235A1 ARP100100298A ARP100100298A AR075235A1 AR 075235 A1 AR075235 A1 AR 075235A1 AR P100100298 A ARP100100298 A AR P100100298A AR P100100298 A ARP100100298 A AR P100100298A AR 075235 A1 AR075235 A1 AR 075235A1
- Authority
- AR
- Argentina
- Prior art keywords
- indol
- derivatives
- anticancer agents
- hydroxyalkyl
- cancer
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso para el tratamiento del cáncer, así como composiciones farmacéuticas para el tratamiento de cáncer, así como composiciones farmacéuticas que comprenden dichos compuestos de la formula (1) y el proceso de preparacion. Reivindicacion 1: Un compuesto de la formula (1) incluyendo cualquiera de sus formas estereoquímicamente isoméricas, en donde R1es hidroxialquilo C1-6 o alquenilo C2-6; siempre que el sustituyente R1 esté ubicado en la posicion 6 o 7 del resto indol; R2 es hidrogeno o alquilo C1-4; Z es un radical seleccionado de las formulas (2) o (3); R3 es hidrogeno o hidroxialquilo C1-4; R4 es hidroxi o alquiloxi C1-4; R5 H o alquilo C1-4; o R4 y R5 se toman juntos para formar oxo; una de sus sales farmacéuticamente aceptables o uno de sus solvatos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09152089 | 2009-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075235A1 true AR075235A1 (es) | 2011-03-16 |
Family
ID=40738626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100298A AR075235A1 (es) | 2009-02-04 | 2010-02-03 | Derivados de indol como agentes anticancer. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8541442B2 (es) |
| EP (1) | EP2393801B1 (es) |
| JP (1) | JP5612611B2 (es) |
| KR (1) | KR101730407B1 (es) |
| CN (1) | CN102307868B (es) |
| AR (1) | AR075235A1 (es) |
| AU (1) | AU2010210178B2 (es) |
| BR (1) | BRPI1008855B8 (es) |
| CA (1) | CA2749209C (es) |
| CL (1) | CL2011001860A1 (es) |
| CO (1) | CO6341625A2 (es) |
| EA (1) | EA021883B1 (es) |
| ES (1) | ES2639752T3 (es) |
| IL (1) | IL214427A (es) |
| MX (1) | MX2011008195A (es) |
| MY (1) | MY152018A (es) |
| NO (1) | NO20111199A1 (es) |
| NZ (1) | NZ594186A (es) |
| SG (1) | SG173495A1 (es) |
| TW (1) | TWI476189B (es) |
| UA (1) | UA107455C2 (es) |
| WO (1) | WO2010089327A2 (es) |
| ZA (1) | ZA201105695B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2841517B2 (ja) | 1989-08-11 | 1998-12-24 | 株式会社ツムラ | 入浴剤 |
| JP2872763B2 (ja) | 1990-06-28 | 1999-03-24 | 紀伊産業株式会社 | 携帯用肛門洗浄器 |
| CA2853729A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
| CN108239083B (zh) | 2016-12-26 | 2021-08-17 | 阿里根公司 | 芳香烃受体调节剂 |
| CN106632303A (zh) * | 2017-01-09 | 2017-05-10 | 湖南华腾制药有限公司 | 一种6‑噻唑基吲哚衍生物的制备方法 |
| TW201925194A (zh) | 2017-11-20 | 2019-07-01 | 美商雅里俊公司 | 吲哚化合物及其用途 |
| CN108659003B (zh) * | 2018-04-14 | 2021-01-26 | 上海朝晖药业有限公司 | 一种治疗口腔溃疡的化合物的制备方法 |
| TW202039443A (zh) * | 2019-01-04 | 2020-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | ６－側氧基－１，６－二氫噠嗪類衍生物、其製備方法及其在醫藥上的應用 |
| WO2020169042A1 (zh) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| AU2020258394A1 (en) | 2019-04-15 | 2021-10-28 | Ariagen, Inc. | Chiral indole compounds and their use |
| WO2024102758A2 (en) * | 2022-11-08 | 2024-05-16 | The General Hospital Corporation | N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| AUPO863197A0 (en) | 1997-08-18 | 1997-09-11 | Fujisawa Pharmaceutical Co., Ltd. | Novel derivatives |
| US6309492B1 (en) | 1998-09-16 | 2001-10-30 | Marc A. Seidner | Polymer fill coating for laminate or composite wood products and method of making same |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| HUP0201215A2 (en) | 1998-12-02 | 2002-08-28 | Pfizer Prod Inc | Methods and compositions for restoring conformational stability of a protein of the p53 family |
| AU1734401A (en) | 1999-12-09 | 2001-06-18 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
| KR20030029997A (ko) | 2000-09-15 | 2003-04-16 | 아노르메드 인코포레이티드 | 케모킨 수용체 결합 헤테로사이클릭 화합물 |
| CZ305838B6 (cs) * | 2001-03-29 | 2016-04-06 | Eli Lilly And Company | N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6 |
| US20030149038A1 (en) | 2001-11-09 | 2003-08-07 | The Regents Of The University Of California | Alpha-helix mimicry by a class of organic molecules |
| CN1596114A (zh) | 2001-11-13 | 2005-03-16 | 三维药物公司 | 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用 |
| ATE389400T1 (de) | 2001-12-18 | 2008-04-15 | Hoffmann La Roche | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren |
| GB0215650D0 (en) | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
| SG155941A1 (en) * | 2004-09-22 | 2009-10-29 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between mdm2 and p53 |
| DE602007007065D1 (de) | 2006-03-22 | 2010-07-22 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| CA2644643C (en) | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| US20100129933A1 (en) * | 2007-04-26 | 2010-05-27 | Forschungszentrum Karlsruhe Gmbh | Method for detecting the binding between mdm2 and the proteasome |
| PA8792401A1 (es) * | 2007-08-06 | 2009-03-31 | Janssen Pharmaceutica Nv | Fenilendiaminas |
| JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
| ES2382701T3 (es) | 2007-09-21 | 2012-06-12 | Janssen Pharmaceutica, N.V. | Inhibidores de la interacción entre MDM2 y p53 |
-
2010
- 2010-02-03 AR ARP100100298A patent/AR075235A1/es unknown
- 2010-02-03 TW TW099103103A patent/TWI476189B/zh not_active IP Right Cessation
- 2010-02-03 US US13/147,707 patent/US8541442B2/en not_active Expired - Fee Related
- 2010-02-03 AU AU2010210178A patent/AU2010210178B2/en not_active Ceased
- 2010-02-03 EP EP10702310.3A patent/EP2393801B1/en active Active
- 2010-02-03 NZ NZ594186A patent/NZ594186A/xx not_active IP Right Cessation
- 2010-02-03 EA EA201170997A patent/EA021883B1/ru not_active IP Right Cessation
- 2010-02-03 KR KR1020117020348A patent/KR101730407B1/ko not_active Expired - Fee Related
- 2010-02-03 SG SG2011055431A patent/SG173495A1/en unknown
- 2010-02-03 CN CN201080007001.9A patent/CN102307868B/zh not_active Expired - Fee Related
- 2010-02-03 MX MX2011008195A patent/MX2011008195A/es active IP Right Grant
- 2010-02-03 JP JP2011548674A patent/JP5612611B2/ja not_active Expired - Fee Related
- 2010-02-03 ES ES10702310.3T patent/ES2639752T3/es active Active
- 2010-02-03 BR BRPI1008855A patent/BRPI1008855B8/pt not_active IP Right Cessation
- 2010-02-03 MY MYPI2011003583 patent/MY152018A/en unknown
- 2010-02-03 CA CA2749209A patent/CA2749209C/en active Active
- 2010-02-03 WO PCT/EP2010/051316 patent/WO2010089327A2/en not_active Ceased
- 2010-03-02 UA UAA201109449A patent/UA107455C2/uk unknown
-
2011
- 2011-07-12 CO CO11087033A patent/CO6341625A2/es not_active Application Discontinuation
- 2011-08-02 ZA ZA2011/05695A patent/ZA201105695B/en unknown
- 2011-08-02 CL CL2011001860A patent/CL2011001860A1/es unknown
- 2011-08-03 IL IL214427A patent/IL214427A/en active IP Right Grant
- 2011-09-02 NO NO20111199A patent/NO20111199A1/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075235A1 (es) | Derivados de indol como agentes anticancer. | |
| AR082826A2 (es) | Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| CR10712A (es) | Derivados de quinazolinona 5-sustituidos como agentes antitumorales | |
| ECSP088114A (es) | Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| UY29702A1 (es) | Inhibidores macrocíclicos del virus de hepatitis c | |
| CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CO7400872A2 (es) | Derivados sustituidos de ftalazin-1(2h)-ona | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| ECSP078053A (es) | Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia | |
| AR078722A1 (es) | Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol | |
| CL2012000925A1 (es) | Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras. | |
| AR071857A1 (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR090955A1 (es) | Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih | |
| CL2021002110A1 (es) | Hidroxipiridoxazepinas como activadores de nrf2. | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| AR060427A1 (es) | Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |